Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,053 matching trials from the live ClinicalTrials.gov search.
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
Conditions
Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions
ADX-324, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
silk fibroin-based incision dressing, cyanoacrylate-based closure system
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
14 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Dyspepsia
Interventions
in vitro and in vivo allergy testing
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Etanercept for the Treatment of Chronic Urticaria

NCT01030120
Conditions
Chronic Idiopathic Urticaria
Interventions
etanercept, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Urticaria Chronic
Interventions
Briquilimab
Drug
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more
Recruiting No phase listed Observational

Post-market Safety Study of LUMISIGHT

NCT07572162
Conditions
Hypersensitivity Reactions
Interventions
Not listed
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Mobile, Alabama • Palo Alto, California
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Conditions
Atopic Dermatitis, Eczema
Interventions
Dilute vinegar (acetic acid), Dilute bleach
Other
Lead sponsor
University of Arizona
Other
Eligibility
5 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Infertility
Interventions
Tamoxifen, Letrozole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Atopic Dermatitis
Interventions
FB825, Placebo
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Fountain Valley, California • Fremont, California • Los Angeles, California + 3 more
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Innovaderm Research Inc.
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more
Conditions
Atopic Dermatitis
Interventions
LEO 138559, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Completed Phase 4 Interventional Results available

VANOS Cream and Skin Barrier Function

NCT00819507
Conditions
Atopic Dermatitis
Interventions
Fluocinonide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Accepts healthy volunteers

Interferon Responses in Eczema Herpeticum

NCT01429311
Conditions
Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Completed No phase listed Observational Accepts healthy volunteers

Molecular and Cellular Characterization of Spongiotic Dermatitis

NCT00371163
Conditions
Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Sacramento, California
Conditions
Atopic Dermatitis
Interventions
ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more
Conditions
Dermatitis, Atopic
Interventions
MK-6194, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
Conditions
Hereditary Angioedema (HAE)
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more